CH Biomedical, an innovative R&D company incubated by the investment section of Baheal Pharmaceutical Group, announced that its new generation of fully magnetically levitated artificial heart was officially approved for marketing.

Qingdao Baheal Medical Inc. and Astellas Pharma China Inc. reached a deeper cooperation agreement on the promotion and operation of Astellas' drugs Betmiga® (mirabellum extended-release tablets), Vesicare® (solifenacin succinate tablets) and Harnal® (tamsulosin hydrochloride extended-release capsules) in mainland China.

On June 30, 2021, Qingdao Baheal Medical Inc. (refer ro “Baheal Medical”, Stock Code: 301015) landed on ChiNext Board of Shenzhen Stock Exchange. On the first day of listing, the stock of Baheal Medicine opened at RMB 35.10 per share, up 359.42%.

(May 13, 2021, Shanghai, China) During the China Beauty Expo, Qingdao Baheal Medical INC. (hereinafter referred to as "Baheal Medical") announced the launch of the country's first commercialization platform for efficacious cosmetics. Baheal Medical is committed to empowering efficacious cosmetic brands to enter the market from three dimensions: medical access standards, consumer experience upgrade, and precise marketing solutions.

On April 16, the "Future Healthcare 100" list was announced at the 5th Future Healthcare 100 Conference. Baheal Intelligent Technology, Easy Referral and Suzhou CHBiomedical, which are incubated by Baheal Investment, a subsidiary of Baheal Pharmaceutical Group, were all honored in the "Future Healthcare Rankings Top 100" list. In addition, Mr. Fu Gang, Chairman of Baheal Pharmaceutical Group, was awarded the "2020-2021 Future Healthcare VB100 - WELAN Award -Best Performing Entrepreneur in Health